Abstract
There are an increasing number of articles showing that existing drugs may have beneficial effects on the atheroma lesion.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Sheperd J, Blaw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of cardiovascular disease (PROSPER) randomized trial. Lancet 2002;360:1623–1630.
Volpe M, Tocci G. Integrated cardiovascular risk management for the future: lessons learned from the ASCOT trial. Aging Clin Exp Res 2005;17(4 suppl):46–53.
Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 2002;8(11):1257–1262.
Kurata T, Kurata M, Okada T. Cervastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia. J Int Med Res 2001;29:329–334.
Dechend R, Gieffers J, Dietz R, et al. Hydroxymethyl glutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation. Circulation 2003;108(3):261–265.
Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethyl glutaryl coenzyme A reductase inhibitors modify the inflammatory response in human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation 2000;101(15): 1760–1763.
Erkkila L, Jauhiainen M, Laitinen K, et al. Effect of Simvastatin, an established lipidlowering drug, on pulmonary Chlamydia pneumoniae infection in mice. Antimicrob Agents Chemother 2005;49(9):3050–3062.
Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I kappa B kinase-beta. Nature (Lond) 1998;396:77–80.
Tiran A, Gruber HJ, Graier WF, et al. Aspirin inhibits Chlamydia pneumoniaeinduced nuclear factor kappa-B activation, cytokine expression, and bacterial development in human endothelial cells. Arterioscler Thromb Vasc Biol 2002;22(7): 1075–1080.
Yoneda H, Miura K, Matshushima H, et al. Aspirin inhibits Chlamydia pneumoniae-induced NF-kappa activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates Chlamydia growth. J Med Microbiol 2003;52:409–415.
Fox KM. EUROPA Study. Lancet 2003;362:782–788.
Schartzkopf B. Repair of coronary arteries after treatment with perindopril in hypertensive heart disease. Hypertension 2000;36:220–251.
Pehrsson SK, Linnersjo A, Hammar N. Cancer risk in patients with ischaemic syndromes. J Int Med 2000;258(2):124–132.
Hossain MS, Easmin S, Islam MS, et al. (2004) Novel thyocyanato complexes with potent cytotoxic and antimicrobial properties. J Pharm Pharmacol 2003;56(12): 1519–1525.
Coghlan A. Shapely vaccine targets: Chlamydia. New Sci 1996;152:18.
Makela PH. Is cardiovascular disease preventable by vaccination? Ann Med 1999;31(1):61–65.
Christianen G, Pedersen A-S, Hjerno K, et al. Potential relevance of Chlamydia pneumoniae surface proteins to an effective vaccine. J Infect Dis 2000;18(suppl 3): S328–S337.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). Other Treatment Possibilities. In: Chlamydia Atherosclerosis Lesion. Springer, London. https://doi.org/10.1007/978-1-84628-810-4_25
Download citation
DOI: https://doi.org/10.1007/978-1-84628-810-4_25
Publisher Name: Springer, London
Print ISBN: 978-1-84628-809-8
Online ISBN: 978-1-84628-810-4
eBook Packages: MedicineMedicine (R0)